Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 28, 2009

DrStockPick.com Stock Report!

PWRM, STEM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

Hana Biosciences is a company that is clearly moving in the right direction. The company’s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.

The young California Company announced there is a definite agreement in place with accredited investors to sell units consisting of common stocks and warrants which will result in total cash proceeds of $12.4 million the closing of which is expected to occur prior to October 9th with Piper Jaffray and Co. serving as exclusive place agent for the transaction.

The net proceeds of this offering will be used to support the completion of the pivotal Phase 2 clinical trial of Marquibo in adult patients with Philadelphia Chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The

Raptor Pharmaceutical Corp., a company focused on accelerating the speed of new treatment to patients by improving existing therapeutics, yesterday announced the appointment of Llew Keltner, M.D., Ph.D., to the company’s board of directors.

Dr. Keltner currently serves as CEO and president of Light Sciences Oncology, a privately held biotechnology company focused on late-stage, light-activated therapy for hepatocellular cancer and solid tumors. Dr. Keltner is also the CEO of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company he founded in 1972.

Christopher M. Starr, Ph.D., CEO of Raptor, said Dr. Keltner’s more than 30 years of experience in the healthcare industry and his focus on cancer and genetic analyses will greatly benefit the company and its progress to develop programs to address cancers, genetic diseases and liver disorders, as well as overall company growth.

“Dr. Keltner has also advised health care and financial companies through the challenges

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, ENZ, IMUC, IWEB, PHC, SVUL, SRCO, SVUL, XSNX

Markets extended their winning streak yet again this week, as all ten sectors of the S&P 500 finished in positive territory and markets hit fresh highs for the year once again, despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow ended up 2.2% on the week, gaining 214 points to close at 9820 on the week, up 11.9% on the year. The Nasdaq performed slightly better, gaining 2.5% on the week, closing at 2132, up 35.2% on the year, while the S&P 500 and Russell 2000 gained 2.5% and 4.1% respectively, up 18.3% and 23.7% on the year.

While it was a relatively quiet week as far as headlines were concerned, there were some positive economic developments in the form

PWRM, Power 3 Medical Products Inc, PWRM.OB

STEM, StemCells, Inc.

DrStockPick.com Report!

Dr Stock Pick HOT News & Alerts!

PWRM, Power 3 Medical Products Inc. and STEM, StemCells, Inc., Tracking

The Footprints of Disease

Thursday September 10, 2009

************************************************************** STEM, StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder

STEM is focused on the development and commercialization of cell-based technologies. In its therapeutic product development programs, STEM is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that

PWRM, Power 3 Medical Products Inc, PWRM.OB

STEM, StemCells, Inc.

DrStockPick.com Report!

Dr Stock Pick HOT News & Alerts!

STEM, StemCells, Inc. and PWRM, Power 3 Medical Products Inc, Tracking

The Footprints of Disease

Wednesday September 9, 2009

************************************************************** STEM, StemCells, Inc.

STEM is focused on the development and commercialization of cell-based technologies. In its therapeutic product development programs, STEM is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. STEM also markets specialty cell culture media

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, FMTI, ICLK, IMUC, IWEB, OMCM, ONEZ, SIHI, TAGS

Markets took pause from their four week run this week, as some less than encouraging economic reports coupled with profit taking led to slight declines in all of the major indices. All told, the Dow ended the week down 0.5%, surrendering 48 points to close at 9321, bringing its YTD gains to 6.2%. The Nasdaq was off 0.7%, closing at 1985, up a healthy 25.9% on the year, while the S&P 500 and Russell 2000 were down 0.6% and 1.5% respectively, paring their yearly gains to 11.2% and 12.9%.

Disappointing economic data relating to inventories and consumer sentiment soured the mood for much of the week, as worse than expected declines in retail sales, consumer sentiment, and business and wholesale inventories gave investors cause for concern. Retail sales

Somaxon Pharmaceuticals, Inc.

(Public, NASDAQ:SOMX)

StocksHaven Investments profiles one of the most promising biomedical pharmaceutical company involved with a PDUFA with regards to a drug which could quite possibly revolutionize the treatment for insomnia, a condition affecting over 70 million Americans. The company has been making waves the past few months as investors and institutions gain confidence from the highly positive clinical trials, and the recent exclusive meeting with the FDA with regards to their NDA. Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The lead product candidate is Silenor® (doxepin) for the treatment of insomnia. The FDA decision date on Silenor has been set to 12/4/09 for their NDA resubmission, the

Viral Genetics Inc. is a company that discovers and develops drug compounds to treat diseases such as cancer, Lyme disease, and HIV. The company discovers and develops immune-based therapies for autoimmune diseases using their thymus nuclear protein compound (TNP).

Viral Genetics recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, PhD. This technology appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials.

Thymus Nuclear Protein (TNP) is the core of their initial approach to the development of immune-based therapies. The company’s lead product candidate is VGV-1. It is an investigational treatment for HIV/AIDS, consisting of TNP suspended in adjuvant. TNP proteins were originally studied as a means of early-detection of certain cancers.

In early pilot studies, the company learned that if the protein was introduced